[go: up one dir, main page]

UA80393C2 - Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице - Google Patents

Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице Download PDF

Info

Publication number
UA80393C2
UA80393C2 UA2003076286A UA2003076286A UA80393C2 UA 80393 C2 UA80393 C2 UA 80393C2 UA 2003076286 A UA2003076286 A UA 2003076286A UA 2003076286 A UA2003076286 A UA 2003076286A UA 80393 C2 UA80393 C2 UA 80393C2
Authority
UA
Ukraine
Prior art keywords
sodium
acid
composition according
droplets
excipients
Prior art date
Application number
UA2003076286A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ранго Дітріх
Рудольф Ліндер
Хартмут Ней
Original Assignee
Алтана Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алтана Фарма Аг filed Critical Алтана Фарма Аг
Publication of UA80393C2 publication Critical patent/UA80393C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение относится к области фармацевтической технологии и касается новой композиции, которая содержит действующее вещество, выбранное из группы ингибиторов ФДЭ 4. В новой композиции действующее вещество практически однородно диспергировано в матрице эксципиента, которая содержит один или несколько эксципиентов, выбранных из группы, включающей жирный спирт, триглицерид, неполный глицерид и эфир жирной кислоты, и при этом композиция находится в форме, которая состоит из микросфер.
UA2003076286A 2000-12-07 2001-06-12 Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице UA80393C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126847 2000-12-07
PCT/EP2001/014307 WO2002045693A1 (en) 2000-12-07 2001-12-06 Pharmaceutical preparation comprising an active dispersed on a matrix

Publications (1)

Publication Number Publication Date
UA80393C2 true UA80393C2 (ru) 2007-09-25

Family

ID=8170601

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003076286A UA80393C2 (ru) 2000-12-07 2001-06-12 Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице

Country Status (28)

Country Link
US (2) US7175854B2 (ru)
EP (1) EP1341527B1 (ru)
JP (1) JP4950409B2 (ru)
KR (1) KR20030072557A (ru)
CN (2) CN1523980A (ru)
AT (1) ATE519481T1 (ru)
AU (2) AU1607302A (ru)
BR (1) BR0115987A (ru)
CA (1) CA2430828C (ru)
CY (1) CY1112333T1 (ru)
CZ (1) CZ20031881A3 (ru)
DK (1) DK1341527T3 (ru)
EA (1) EA007151B1 (ru)
EE (1) EE05256B1 (ru)
ES (1) ES2371060T3 (ru)
HR (1) HRP20030493B1 (ru)
HU (1) HUP0400566A3 (ru)
IL (2) IL155964A0 (ru)
MX (1) MXPA03005092A (ru)
NO (1) NO333722B1 (ru)
NZ (1) NZ526015A (ru)
PL (1) PL206595B1 (ru)
PT (1) PT1341527E (ru)
SG (1) SG148028A1 (ru)
SI (1) SI1341527T1 (ru)
UA (1) UA80393C2 (ru)
WO (1) WO2002045693A1 (ru)
ZA (1) ZA200305114B (ru)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
UA80393C2 (ru) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
CN100536844C (zh) * 2000-12-07 2009-09-09 尼科梅德有限责任公司 包含酸不稳定活性成分的糊剂形式的药物制剂
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
AU2002342917A1 (en) * 2001-11-19 2003-06-10 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
FR2834894B1 (fr) * 2002-01-21 2004-02-27 Servier Lab Composition pharmaceutique orodispersible de piribedil
FR2834890B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
FR2834896B1 (fr) * 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'ivabradine
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
CA2490142A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
WO2004011001A1 (ja) 2002-07-31 2004-02-05 Senju Pharmaceutical Co., Ltd. 水性液剤および光安定化された水性液剤
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
CA2395931A1 (en) * 2002-08-07 2004-02-07 Bernard Charles Sherman Solid compositions comprising gabapentin having improved stability
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
AR045142A1 (es) * 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
AU2004291149C1 (en) 2003-11-17 2021-01-21 Biomarin Pharmaceutical Inc. Methods and Compositions for the Treatment of Metabolic Disorders
US7955620B2 (en) * 2003-12-23 2011-06-07 Sun Pharmaceutical Industries Limited Stable oral composition
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1748756B1 (en) 2004-03-10 2009-04-29 Bayer Schering Pharma Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
KR100681660B1 (ko) * 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
ES2629682T3 (es) 2004-03-29 2017-08-14 University Of South Florida Tratamiento efectivo de tumores y cáncer con fosfato de triciribina
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CN100345544C (zh) * 2004-06-10 2007-10-31 范敏华 一种尼麦角林口腔崩解片剂及其制备方法
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
CA2582300A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
AU2005306686B2 (en) * 2004-11-17 2011-06-02 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
EP2258350B1 (en) 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
KR100706036B1 (ko) * 2005-04-04 2007-04-11 대화제약 주식회사 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
SG166106A1 (en) * 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
EP1965761B1 (de) * 2005-12-21 2015-07-01 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
JP2007210905A (ja) * 2006-02-07 2007-08-23 Asahi Breweries Ltd 口腔内用顆粒、錠剤およびその製造方法
CN1915233B (zh) * 2006-08-30 2012-10-03 四川科瑞德制药有限公司 一种治疗焦虑症的药物组合物及其口崩制剂
WO2008031928A1 (fr) * 2006-09-14 2008-03-20 Pierre Fabre Medicament Utilisation du milnacipran pour diminuer les proprietes recompensantes de l'alcool pendant ou apres un traitement de sevrage alcoolique
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
KR100815029B1 (ko) * 2006-11-29 2008-03-18 부광약품 주식회사 독소필린 서방출성 제제
GB2461822B (en) * 2007-03-20 2011-09-21 Isp Investments Inc Meltable binder for melt granulation and/or pelletization
ES2639130T3 (es) * 2007-06-06 2017-10-25 Basf Se Formulación farmacéutica para la fabricación de comprimidos de rápida desintegración
ES2646112T3 (es) * 2007-06-06 2017-12-12 Basf Se Formulación farmacéutica para la fabricación de comprimidos que se desintegran rápidamente
EP2152263A1 (en) * 2007-06-07 2010-02-17 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
CN101939004A (zh) * 2008-01-25 2011-01-05 阿尔法制药有限公司 度洛西汀的缓释药物组合物
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
MX2009004635A (es) * 2009-04-29 2010-10-29 Univ Autonoma Metropolitana Formas farmaceúticas solubles de la n,n´-diamino-difenilsulfona para su uso óptimo en el tratamiento de diversas enfermedades.
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
UA102070C2 (ru) * 2009-12-16 2013-06-10 Общество С Ограниченной Ответственностью "Фармацевтическая Группа "Здоровье" Применение фармацевтической композиции, которая содержит (s)-2-амино-5-гуанидинопентановой кислоты (s)-2-аминоглутарат, для лечения и профилактики патологий беременности
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2579858B1 (en) * 2010-06-14 2014-05-21 Ratiopharm GmbH Ivabradine-containing pharmaceutical composition
CN101879139A (zh) * 2010-06-23 2010-11-10 广西方略药业集团有限公司 一种治疗消化性疾病的肠溶制剂及其制备方法
CN102309442A (zh) * 2010-07-07 2012-01-11 澳美制药厂 盐酸氨溴索口服水性组合物及其制备方法
CN102309460B (zh) * 2010-07-09 2013-04-24 重庆医科大学 溴吡斯的明掩味口腔崩解片及其制备方法
EP2543364A1 (en) * 2010-10-14 2013-01-09 Deva Holding Anonim Sirketi Formulations of cetyl myristate and/or cetyl palmitate
FR2967067A1 (fr) * 2010-11-10 2012-05-11 Sanofi Aventis Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
RU2482847C2 (ru) * 2010-11-17 2013-05-27 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая силденафил или алпростадил, миноксидил или эуфиллин, тестостерон или йохимбин и липосомы для местного применения
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
EP2734207A4 (en) * 2011-07-18 2015-06-17 Tokai Pharmaceuticals Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
WO2013056079A1 (en) * 2011-10-13 2013-04-18 The Johns Hopkins University High affinity beta lactamase inhibitors
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9717678B2 (en) * 2011-11-06 2017-08-01 Murty Pharmaceuticals, Inc. Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
JP6400580B2 (ja) * 2012-08-13 2018-10-03 アディファルム・エアドゥ ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
CN102988297A (zh) * 2012-12-21 2013-03-27 无锡泓兴生物医药科技有限公司 罗氟司特固体分散体及含有其的药物组合物
EP2948148B1 (en) * 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
GEAP201814057A (en) * 2013-07-11 2018-03-26 Tasly Pharmaceutical Group Co Traditional chinese medicine composition, and preparation and application thereof
GEAP201814056A (en) 2013-07-11 2018-06-25 Tasly Pharmaceutical Group Co Micro-drop-pill-shaped compound and preparation method thereof
AU2014289766B2 (en) 2013-07-11 2019-03-14 Tasly Pharmaceutical Group Co., Ltd. Traditional chinese medicine composition, and preparation and application thereof
CA2915445C (en) 2013-07-19 2024-04-23 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
KR101399514B1 (ko) * 2013-10-28 2014-05-27 에스케이케미칼주식회사 폴라프레징크를 함유하는 안정한 정제 제형
EA201992230A1 (ru) 2013-12-04 2020-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
WO2015132708A1 (en) * 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
CN104434811A (zh) * 2014-11-07 2015-03-25 浙江大学 一种可嵌于人工晶状体襻上的药物缓释微球及其制备方法
US9710054B2 (en) 2015-02-28 2017-07-18 Intel Corporation Programmable power management agent
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN113081991B (zh) * 2015-06-03 2022-07-15 南京三迭纪医药科技有限公司 药品剂型及其使用
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
WO2017160106A2 (ko) 2016-03-16 2017-09-21 한미약품 주식회사 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
WO2019059652A1 (ko) * 2017-09-19 2019-03-28 경상대학교 산학협력단 맛이 차폐된 경구투여용 약학적 제제 및 이의 제조 방법
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
WO2019236374A2 (en) 2018-06-04 2019-12-12 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CN110051633A (zh) * 2018-11-27 2019-07-26 宁夏医科大学 一种环维黄杨星d纳米制剂及其制备方法
CN111840308B (zh) * 2019-07-18 2022-03-01 北京市农林科学院 6种小分子药物在抑制犬细小病毒中的应用
CN111000844B (zh) * 2019-12-19 2022-06-28 浙江立恩生物科技有限公司 一种治疗流感病毒感染的药物
EP4119129A4 (en) * 2020-03-11 2024-01-24 Sawai Pharmaceutical Co., Ltd. GRANULES AND THEIR USE
US20230372249A1 (en) 2020-09-04 2023-11-23 Elanco Us Inc. Palatable formulations
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
CN112546000B (zh) * 2020-12-30 2023-06-20 海南海神同洲制药有限公司 一种盐酸克林霉素棕榈酸酯干混悬剂及其制备方法
CN113662920A (zh) * 2021-09-28 2021-11-19 南京长澳医药科技有限公司 一种比拉斯汀口腔崩解片及其制备方法
EP4456870A1 (en) 2021-12-28 2024-11-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
CN114796127B (zh) * 2022-05-16 2025-03-07 北京斯利安药业有限公司 伊来西胺缓释干混悬剂及其制备方法
JP2025530005A (ja) 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物
CN121154557B (zh) * 2025-11-21 2026-01-30 内蒙古鸿信达生物药业有限公司 一种含地克珠利的复方抗球虫制剂制备方法

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
DE3269604D1 (en) 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
GB8415540D0 (en) 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS625966A (ja) 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (en) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
NZ221996A (en) 1986-10-07 1989-08-29 Yamanouchi Pharma Co Ltd Imidazo-pyridine derivatives and pharmaceutical compositions
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
CA1327796C (en) 1987-07-16 1994-03-15 Jorg Senn-Bilfinger Diazoles
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
WO1990005136A1 (de) 1988-11-07 1990-05-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue imidazopyridine
KR900014376A (ko) 1989-03-13 1990-10-23 후지사와 토모키치로 이미다조 피리딘 화합물 및 그것의 제조방법
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
JPH0331280A (ja) 1989-06-28 1991-02-12 Fujisawa Pharmaceut Co Ltd 新規イミダゾピリジン化合物
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DK0480052T3 (da) 1990-03-28 1998-05-11 Otsuka Pharma Co Ltd Quinolinderivat, antiulcus-lægemiddel indeholdende derivatet og fremstilling af derivatet
JP2816227B2 (ja) 1990-03-30 1998-10-27 日清製粉株式会社 抗潰瘍薬
JP2851117B2 (ja) 1990-03-30 1999-01-27 日清製粉株式会社 インドール誘導体およびそれらを有効成分とする抗潰瘍薬
IL97931A0 (en) 1990-04-27 1992-06-21 Byk Gulden Lomberg Chem Fab Pyridazine derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1992006979A1 (de) 1990-10-15 1992-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue diazine
MA22401A1 (fr) 1991-01-29 1992-10-01 Smithkline Beecham Intercredit Procede de preparation de sels de guinoleine
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
EP0587744B1 (en) * 1991-05-28 2003-07-16 McNEIL-PPC, Inc. Chewable drug-delivery composition
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
DE59209687D1 (de) 1991-10-25 1999-06-02 Byk Gulden Lomberg Chem Fab Pyrrolo-pyridazine mit magen- und darmschutzwirkungen
GB9126438D0 (en) 1991-12-12 1992-02-12 Smithkline Beecham Intercredit New quinoline derivatives
GB9201694D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9201692D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JP3523275B2 (ja) 1992-03-26 2004-04-26 東光薬品工業株式会社 貼付剤
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO1994024130A1 (de) 1993-04-22 1994-10-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
US5556863A (en) 1993-06-11 1996-09-17 Astra Aktiebolag Compound for gastric acid secretion inhibition
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (ru) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСИАЛКИЛКАРБАМАТЫ ИМИДАЗО[1,2-а]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ
SE9401197D0 (sv) 1994-04-11 1994-04-11 Astra Ab Active compounds
EP0773946B1 (de) 1994-07-28 2002-03-27 Byk Gulden Lomberg Chemische Fabrik GmbH Imidazopyridin-azolidinone
JPH0959152A (ja) 1995-08-18 1997-03-04 Teisan Seiyaku Kk 硝酸イソソルビド含有貼付剤
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
US5677302A (en) * 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
CA2289542A1 (en) 1997-05-28 1998-12-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Fused dihydropyrans
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
HUP0001555A3 (en) 1997-10-30 2001-01-29 Altana Pharma Ag Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
PT1037607E (pt) * 1997-12-08 2004-07-30 Altana Pharma Ag Nova forma de supositorio compreendendo um composto activo instavel em acido
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
JP4370429B2 (ja) 1998-09-10 2009-11-25 東和薬品株式会社 徐放性マイクロスフエアの製造法
EA005377B1 (ru) 1998-09-23 2005-02-24 Алтана Фарма Аг ТЕТРАГИДРОИМИДАЗО [1,2-h][1,7] НАФТИРИДИНОВЫЕ СОЕДИНЕНИЯ
JP2002528548A (ja) 1998-11-03 2002-09-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング イミダゾナフチリジン
ES2199810T3 (es) 1999-04-17 2004-03-01 Altana Pharma Ag Haloalcoxi-imidazonaftiridinas.
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
CA2376202C (en) * 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
UA80393C2 (ru) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
BR0115986A (pt) * 2000-12-07 2003-12-23 Altana Pharma Ag Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤

Also Published As

Publication number Publication date
ZA200305114B (en) 2004-05-12
HUP0400566A3 (en) 2012-09-28
EA200300634A1 (ru) 2003-12-25
HUP0400566A2 (hu) 2004-06-28
NO333722B1 (no) 2013-09-02
PL362323A1 (en) 2004-10-18
HRP20030493A2 (en) 2005-06-30
EP1341527A1 (en) 2003-09-10
CN101810592A (zh) 2010-08-25
SI1341527T1 (sl) 2011-12-30
CY1112333T1 (el) 2015-12-09
ATE519481T1 (de) 2011-08-15
EA007151B1 (ru) 2006-08-25
WO2002045693A1 (en) 2002-06-13
PT1341527E (pt) 2011-10-04
BR0115987A (pt) 2003-12-23
SG148028A1 (en) 2008-12-31
MXPA03005092A (es) 2003-09-05
AU1607302A (en) 2002-06-18
US7175854B2 (en) 2007-02-13
EE200300235A (et) 2003-08-15
US20070122474A1 (en) 2007-05-31
ES2371060T3 (es) 2011-12-27
JP2004514736A (ja) 2004-05-20
KR20030072557A (ko) 2003-09-15
HRP20030493B1 (hr) 2011-10-31
NO20032593D0 (no) 2003-06-06
CZ20031881A3 (en) 2004-04-14
EE05256B1 (et) 2010-02-15
IL155964A0 (en) 2003-12-23
EP1341527B1 (en) 2011-08-10
NZ526015A (en) 2006-03-31
IL155964A (en) 2012-06-28
US7951398B2 (en) 2011-05-31
US20040058896A1 (en) 2004-03-25
AU2002216073B2 (en) 2006-11-23
CN1523980A (zh) 2004-08-25
DK1341527T3 (da) 2011-10-24
CA2430828C (en) 2010-11-09
JP4950409B2 (ja) 2012-06-13
CA2430828A1 (en) 2002-06-13
PL206595B1 (pl) 2010-08-31
NO20032593L (no) 2003-08-05

Similar Documents

Publication Publication Date Title
US7951398B2 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
AU2002216073A1 (en) Pharmaceutical preparation comprising an active dispersed on a matrix
US7976871B2 (en) Modified release composition of highly soluble drugs
US8268352B2 (en) Modified release composition for highly soluble drugs
CN103271083B (zh) 多功能离子液体组合物
US8263125B2 (en) Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients
US9308181B2 (en) Topical formulations, systems and methods
US20170319698A1 (en) Gastroretentive gel formulations
US20230059204A1 (en) Transdermal micro-dosing delivery of pharmaceutical agents
JP2000514405A (ja) Ｄｈａ―薬剤複合体
US20230277448A1 (en) Chewable formulations
DE10061137A1 (de) Neue pharmazeutische Zubereitung
KR20220126287A (ko) 멀티모달 조성물 및 치료 방법
CA3208345A1 (en) Prodrug compositions and methods of treatment